TRDA
NASDAQ HealthcareEntrada Therapeutics, Inc. - Common Stock
Biotechnology
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $6.87 |
|---|---|
| Volume | 725,658 |
| Market Cap | 266.70M |
| Beta | -0.260 |
| RSI (14-Day) | 45.8 |
| 200-Day MA | $9.62 |
| 50-Day MA | $7.22 |
| 52-Week High | $16.45 |
| 52-Week Low | $4.93 |
| Forward P/E | -2.11 |
| Price / Book | 0.91 |
๐ฏ Investment Strategy Scores
TRDA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (94/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TRDA in your text
Paste any article, transcript, or post โ the tool will extract TRDA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.